Okay.
You talked about securing as much variety as possible, but I want to zero in on variety of production. Of course, AstraZeneca has been mentioned and domestic production is in the news today.
We know that AstraZeneca pledged to provide its vaccine on a not-for-profit basis for the duration of the pandemic and was open to manufacturing partnerships. In fact, Australia, Brazil, Mexico, Argentina, India, Japan, South Korea, China and other countries all negotiated licensing agreements to manufacture the AstraZeneca vaccine domestically and are doing so today.
Can you tell us why Canada failed to secure a similar licensing agreement to manufacture the AstraZeneca vaccine in Canada?